Outputs (406)

Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis (2022)
Journal Article
Gordon, M., Sinopoulou, V., Akobeng, A. K., Pana, M., Gasiea, R., & Moran, G. W. (2022). Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Library, 2022(4), 1-55. https://doi.org/10.1002/14651858.CD007216.pub2

Background: There are a limited number of treatment options for people with corticosteroid-refractory ulcerative colitis. Animal models of inflammatory bowel disease and uncontrolled studies in humans suggest that tacrolimus may be an effective treat... Read More about Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis.

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly (2022)
Journal Article
Guler, S. A., Cuevas-Ocaña, S., Nasser, M., Wuyts, W. A., Wijsenbeek, M. S., Froidure, A., …Moor, C. C. (2022). ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 8(2), https://doi.org/10.1183/23120541.00640-2021

This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translation... Read More about ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly.

ERS International Congress 2021: highlights from the Paediatric Assembly (2022)
Journal Article
Ardura-Garcia, C., Abellan, A., Cuevas-Ocaña, S., Freitag, N., Lam, Y. T., Makrinioti, H., …Pijnenburg, M. W. (2022). ERS International Congress 2021: highlights from the Paediatric Assembly. ERJ Open Research, 8(2), https://doi.org/10.1183/23120541.00643-2021

In this review, Early Career Members of the European Respiratory Society (ERS) and the Chairs of the ERS Assembly 7: Paediatrics present the highlights in paediatric respiratory medicine from the ERS International Congress 2021. The eight scientific... Read More about ERS International Congress 2021: highlights from the Paediatric Assembly.

Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial (2022)
Journal Article
Wang, J. B., Huang, A., Wang, Y., Ji, D., Liang, Q. S., Zhao, J., …Zou, Z. (2022). Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial. Alimentary Pharmacology and Therapeutics, 55(10), 1297-1310. https://doi.org/10.1111/apt.16902

Background Treatment of chronic drug-induced liver injury (DILI) or herb-induced liver injury(HILI) is an important and unresolved challenge. There is no consensus regarding the indications for corticosteroids for chronic DILI/HILI. Aims To inve... Read More about Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial.

Impact of Coexisting Dementia on Inpatient Outcomes for Patients Admitted with a COPD Exacerbation (2022)
Journal Article
Gupta, A., McKeever, T. M., Hutchinson, J. P., & Bolton, C. E. (2022). Impact of Coexisting Dementia on Inpatient Outcomes for Patients Admitted with a COPD Exacerbation. International Journal of Chronic Obstructive Pulmonary Disease, 2022(17), 535-544. https://doi.org/10.2147/copd.s345751

Purpose: People with COPD are at a higher risk of cognitive dysfunction than the general population. However, the additional impact of dementia amongst such patients is not well understood, particularly in those admitted with a COPD exacerbation. We... Read More about Impact of Coexisting Dementia on Inpatient Outcomes for Patients Admitted with a COPD Exacerbation.

Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19 (2022)
Journal Article
Houchen-Wolloff, L., Poinasamy, K., Holmes, K., Tarpey, M., Hastie, C., Raihani, K., …Evans, R. A. (2022). Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax, 77(7), 717-720. https://doi.org/10.1136/thoraxjnl-2021-218582

Given the large numbers of people infected and high rates of ongoing morbidity, research is clearly required to address the needs of adult survivors of COVID-19 living with ongoing symptoms (long COVID). To help direct resource and research efforts,... Read More about Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19.

Patient-reported respiratory outcome measures in the recovery of adults hospitalised with COVID-19: A systematic review and meta-analysis (2022)
Working Paper
Middleton, S., Chalitsios, C., McKeever, T. M., Jenkins, A. R., & Bolton, C. E. Patient-reported respiratory outcome measures in the recovery of adults hospitalised with COVID-19: A systematic review and meta-analysis

Background Acute COVID-19 clinical symptoms have been clearly documented, but long-term functional and symptomatic recovery from COVID -19 is less well described. Methods A systematic review and meta-analysis were conducted to describe patient-rep... Read More about Patient-reported respiratory outcome measures in the recovery of adults hospitalised with COVID-19: A systematic review and meta-analysis.

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab (2022)
Journal Article
Lin, S., Kennedy, N. A., Saifuddin, A., Sandoval, D. M., Reynolds, C. J., Castro Seoane, R., …Jones, G. (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 13, Article 1379. https://doi.org/10.1038/s41467-022-28517-z

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrou... Read More about Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.

Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study (2022)
Journal Article
Withey, S. B., MacPherson, L., Oates, A., Powell, S., Novak, J., Abernethy, L., …Peet, A. C. (2022). Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study. Pediatric Radiology, 52(6), 1134-1149. https://doi.org/10.1007/s00247-021-05266-7

Background Relative cerebral blood volume (rCBV) measured using dynamic susceptibility-contrast MRI can differentiate between low- and high-grade pediatric brain tumors. Multicenter studies are required for translation into clinical practice. Obj... Read More about Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study.

Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial (2022)
Journal Article
Hancox, J., Ayling, K., Bedford, L., Vedhara, K., Robertson, J. F. R., Young, B., …Kendrick., D. (2023). Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial. Journal of Public Health, 45(2), e275–e284. https://doi.org/10.1093/pubmed/fdac032

Background: The Early CDT®-Lung antibody blood test plus serial CT-scans for test-positives reduces late-stage lung cancer presentation. This study assessed psychological outcomes of this approach. Methods: Randomised controlled trial (n=12,208) c... Read More about Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial.